|Dr. Edward M. Kaye||CEO & Director||648.9k||N/A||1949|
|Dr. Adrian R. Krainer||Co-Founder & Director||100k||N/A||1959|
|Dr. Huw M. Nash Ph.D.||COO, Chief Bus. Officer & Sec.||429.67k||N/A||1967|
|Dr. Barry S. Ticho||Chief Medical Officer||501.15k||N/A||1960|
|Ms. Isabel Aznarez||Co-Founder, VP & Head of Biology||N/A||N/A||1972|
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001, to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc. has a partnership with Invitae Corporation to offer epilepsy panel testing. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was founded in 2014 and is headquartered in Bedford, Massachusetts.
Stoke Therapeutics, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 7. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 6; Compensation: 8.